Is AbbVie, Inc. overvalued or undervalued?

As of 27 October 2023, AbbVie, Inc. has moved from an expensive to a very expensive valuation grade. The company is currently considered overvalued based on its financial metrics. Key ratios include a P/E ratio of 23, a Price to Book Value of 240.68, and an EV to EBIT of 23.05, which significantly exceed industry averages. In comparison to its peers, AbbVie’s P/E ratio of 22.80 is higher than Johnson & Johnson's 22.46 but lower than Eli Lilly & Co.'s 48.73, indicating a relative overvaluation. Additionally, AbbVie’s PEG ratio of 1.44 suggests that its growth prospects do not justify its current price level when compared to peers like Merck & Co., Inc., which has a more attractive valuation at a PEG of 0.03. The stock's recent performance shows a decline of 3.72% over the past week, contrasting with the S&P 500's slight decline of 0.13%, reinforcing the notion of overvaluation.